Meredith Fisher is a Partner with Mass General Brigham Ventures where she focuses on early-stage investments and company creation. Previously, she was Director of Private Investments in the private/family office at Bracebridge Capital where she led investments in early-stage life science companies. She previously led business development for Ginkgo BioWorks, was Senior Director at PureTech Ventures, and was a scientist in anti-viral drug discovery for Idenix Pharmaceuticals and Anadys Pharmaceuticals. Meredith currently holds board seats at BraveBio, ClarisBio, FireCyte, Mediar Therapeutics, Nocion Therapeutics, Violet, and ZielBio and serves as a board observer for Scorpion Therapeutics and Amolyt. Meredith holds an undergraduate degree from Mount Holyoke College, an M.B.A. from the MIT Sloan School of Management, and a PhD from Harvard University. While at Harvard, she co-founded Harvard Graduate Women in Science and Engineering (HGWISE).